Retatrutide

Retatrutide

Primary Function: Triple receptor agonist for metabolic regulation and fat loss
Research Use: Obesity, diabetes, energy homeostasis models
Molecular Formula: (Pending full public release)
CAS Number: (Pending)
Synonyms: LY3437943

Description:
Retatrutide is an investigational peptide and triple agonist targeting GIP, GLP-1, and glucagon receptors. Early research suggests powerful effects on energy expenditure, weight loss, and glucose regulation, making it a promising candidate for future obesity and metabolic disorder therapies.

Mechanism of Action:

• Simultaneous activation of GIP, GLP-1, and glucagon receptors
• Boosts insulin secretion and fat oxidation
• Reduces appetite and increases energy expenditure

Key Research Areas:

• Multi-pathway obesity reduction
• Energy expenditure and thermogenesis
• Glucose homeostasis and insulin sensitivity
• Hepatic fat and lipid profile research

History of Discovery:
Developed by Eli Lilly, Retatrutide is one of the newest triple receptor agonists. It’s been engineered to combine the benefits of GIP, GLP-1, and glucagon receptor activation to target multiple pathways involved in metabolic regulation and fat loss.

Case Studies:

1. Obesity Reduction in Early Trials (2023, Preclinical Studies): Initial trials show significant reductions in body fat percentage and improved glucose control in animal models.
2. Energy Expenditure and Thermogenesis (2023, Diabetes Obes Metab): Retatrutide was shown to enhance energy expenditure in obese subjects, promoting greater fat loss and metabolic efficiency.
3. Weight Loss in Metabolic Syndrome (2024, Early Phase 1 Trials): Early human trials report a 13% weight reduction in overweight individuals after 12 weeks of treatment.

Packaging Information:

• Form: Lyophilized powder (research-grade)
• Purity: ≥ 99%
• For research use only. Not for human or veterinary use.